CD80: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of CD80. The page also collects GeneMedi's different modalities and formats products for CD80 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CD80 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
The protein encoded by this gene is a membrane receptor that is activated by the binding of CD28 or CTLA-4. The activated protein induces T-cell proliferation and cytokine production. This protein can act as a receptor for adenovirus subgroup B and may play a role in lupus neuropathy. [provided by RefSeq, Aug 2011]
|Gene Official Name||CD80|
|Gene Alias||B7, B7-1, B7.1, BB1, CD28LG, CD28LG1, LAB7|
|Protein Sub-location||Transmembrane Protein|
|Category||Therapeutics Target, INN Index, Immuno-oncology Target|
Pre-made CD80-specific INN-index biosimilar (antibody&conjugates)-belatacept, Galiximab
Anti-CD80 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
|Cat No.||Products Name (INN Index)||INN Name||Previous Name||Target||Format||Order|
|GMP-Bios-INN-753||Pre-Made Belatacept Biosimilar, Fusion Protein targeting CD80 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting B7/B7-1/B7.1/BB1/CD28LG/CD28LG1/LAB7||belatacept||CD80||Fusion Protein|
|GMP-Bios-ab-229||Pre-Made Galiximab biosimilar, Whole mAb, Anti-CD80 Antibody: Anti-B7/BB1/B7-1/B7.1/LAB7/CD28LG/CD28LG1 therapeutic antibody||Galiximab||CD80||Whole mAb|
Pre-made anti-CD80 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-CD80 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CD80 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
|Cat No.||Antibody Name||Format||Classified by tag||Order|
|GM-Tg-hg-T58238-Ab||Anti-CD80 monoclonal antibody||mab||Biofunctional antibody, Therapeutics Target antibody|